Alnylam Pharmaceuticals Inc (ALNY)vsMiMedx Group Inc (MDXG)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
MDXG
MiMedx Group Inc
$4.10
-0.73%
HEALTHCARE · Cap: $612.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 787% more annual revenue ($3.71B vs $418.63M). MDXG leads profitability with a 11.6% profit margin vs 8.5%. MDXG trades at a lower P/E of 12.9x. MDXG earns a higher WallStSmart Score of 72/100 (B).
ALNY
Hold49
out of 100
Grade: D+
MDXG
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+65.2%
Fair Value
$14.98
Current Price
$4.10
$10.88 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Earnings expanding 99.5% YoY
Every $100 of equity generates 22 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 27.1% year-over-year
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : MDXG
The strongest argument for MDXG centers on EPS Growth, Return on Equity, P/E Ratio. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, PEG Ratio.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while MDXG is a growth play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.60 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
MDXG scores higher overall (72/100 vs 49/100) and 27.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?